Calcium‐channel blockers: Clinical outcome associations with reported pharmacogenetics variants in 32 000 patients

AIMS: Pharmacogenetic variants impact dihydropyridine calcium‐channel blockers (dCCBs; e.g., amlodipine) treatment efficacy, yet evidence on clinical outcomes in routine primary care is limited. Reported associations in pharmacogenomics knowledge base PharmGKB have weak supporting evidence. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Türkmen, Deniz, Masoli, Jane A. H., Delgado, João, Kuo, Chia‐Ling, Bowden, Jack, Melzer, David, Pilling, Luke C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091789/
https://www.ncbi.nlm.nih.gov/pubmed/36134646
http://dx.doi.org/10.1111/bcp.15541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091789/
https://www.ncbi.nlm.nih.gov/pubmed/36134646
http://dx.doi.org/10.1111/bcp.15541

Ejemplares similares